Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

London, Jan 10, 2026, 09:43 GMT — Market closed

Haleon shares closed down 1.18% at 367.50 pence on Friday after the consumer health group set out plans to revamp its operating model, redrawing regional lines and adding new senior roles. A filing showed the changes are due to be in place by mid-2026, even as London’s FTSE 100 logged a record close. (Vox Markets)

The timing matters. Haleon is trying to push its “Win as One” strategy from last year from slides into day-to-day execution, and the market will look for proof in growth and productivity rather than another org chart. Chief executive Brian McNamara said the shift should leave Haleon “a simpler and more agile and efficient organisation.” (Haleon Corporate)

The “operating model” is corporate shorthand for how the business is run — who owns decisions, and who carries the numbers. Haleon plans six “operating units”, regional businesses accountable for performance, including splitting its EMEA and Latin America set-up into three and making India Subcontinent a stand-alone unit separate from Asia Pacific, the announcement said. (Investegate)

Haleon has appointed Filippo Lanzi as Chief Growth Officer and Björn Timelin as Chief Transformation Officer, according to executive team biographies on its website. It also named Kedar Lele to run the new India Subcontinent unit. (Haleon Corporate)

The stock ranged between 365.90p and 373.90p on Friday and Haleon’s market value stands at about £32.7 billion, according to Hargreaves Lansdown data. It is about 12% below its 52-week high of 419.40p and roughly 13% above the 52-week low of 325.10p. (Hargreaves Lansdown)

In New York, Haleon’s ADRs closed down 1.29% at $9.91 on Friday. (StockAnalysis)

The catch is execution. Haleon did not put numbers on any costs, savings or timing bumps in its announcement, and consultation with employee representatives can stretch timetables or force changes. If the reorganisation distracts from selling toothpaste and pain relief in key markets, the market will not wait around.

The next hard catalyst is Haleon’s full-year 2025 results on Feb. 25, when investors expect more detail on the new set-up and what it changes — if anything — about growth, margins and cash flow. The following marker is its first-quarter trading update on April 29. (Haleon Corporate)

Stock Market Today

  • Ipsen Partners with Origami to Expand Rare Disease Pipeline; Shares Seen as Undervalued
    February 1, 2026, 1:59 AM EST. Ipsen (ENXTPA:IPN) announced a global collaboration and option agreement with Origami Therapeutics to develop a novel small molecule for a rare neurodegenerative disorder. This move aligns with Ipsen's focus on rare diseases and neuroscience, aiming to deliver first or best in class therapies. Shares are currently trading about 3.7% above the €132.73 consensus target but flagged as 30.8% undervalued by Simply Wall St's analysis. The stock shows strong short-term momentum with an 18.5% 30-day return. Key risks include execution challenges and reduced profit margins, which fell to 11.9% from 19.3% last year. Investors should monitor clinical milestones and valuation shifts as the program progresses.
Standard Chartered stock in focus: STAN shares slip as €1bn green bond, buyback updates land
Previous Story

Standard Chartered stock in focus: STAN shares slip as €1bn green bond, buyback updates land

Oklo stock jumps on Meta nuclear campus deal — what investors watch before Monday
Next Story

Oklo stock jumps on Meta nuclear campus deal — what investors watch before Monday

Go toTop